Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches

Andrea Berardi; Mohd Kashif Siddiqui; Catrin Treharne; Gerard Harty; Schiffon L. Wong

doi:10.1080/03007995.2019.1585779

Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches

Current Medical Research and Opinion ◽

10.1080/03007995.2019.1585779 ◽

2019 ◽

Vol 35 (8) ◽

pp. 1371-1378 ◽

Cited By ~ 5

Author(s):

Andrea Berardi ◽

Mohd Kashif Siddiqui ◽

Catrin Treharne ◽

Gerard Harty ◽

Schiffon L. Wong

Keyword(s):

Multiple Sclerosis ◽

Patient Characteristics ◽

Comparative Efficacy ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Relapsing Remitting ◽

Indirect Treatment ◽

Meta Regression ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND3 Indirect Treatment Comparison (ITC) Analysis of Therapies That are Often Considered for Treatment-Experienced Patients With Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2012.03.762 ◽

2012 ◽

Vol 15 (4) ◽

pp. A141

Author(s):

F.L. Allen ◽

G. Osei-assibey ◽

R. Arnold ◽

B. Deniz

Keyword(s):

Multiple Sclerosis ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Relapsing Remitting ◽

Indirect Treatment ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

Current Medical Research and Opinion ◽

10.1080/03007995.2020.1747999 ◽

2020 ◽

Vol 36 (7) ◽

pp. 1157-1166 ◽

Cited By ~ 1

Author(s):

Imtiaz A. Samjoo ◽

Evelyn Worthington ◽

Anja Haltner ◽

Chris Cameron ◽

Richard Nicholas ◽

...

Keyword(s):

Multiple Sclerosis ◽

Progressive Multiple Sclerosis ◽

Secondary Progressive Multiple Sclerosis ◽

Indirect Treatment Comparison ◽

Treatment Comparison ◽

Secondary Progressive ◽

Indirect Treatment ◽

Disease Modifying

Download Full-text

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2016.06.001 ◽

2016 ◽

Vol 9 ◽

pp. 23-30 ◽

Cited By ~ 59

Author(s):

Emer Fogarty ◽

Susanne Schmitz ◽

Niall Tubridy ◽

Cathal Walsh ◽

Michael Barry

Keyword(s):

Multiple Sclerosis ◽

Systematic Review ◽

Meta Analysis ◽

Comparative Efficacy ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27

Current Medical Research and Opinion ◽

10.1185/03007995.2014.971359 ◽

2014 ◽

Vol 31 (1) ◽

pp. 51-52 ◽

Cited By ~ 1

Author(s):

Richard Nixon ◽

Gorana Capkun-Niggli ◽

Niklas Bergvall ◽

Sofia Dias

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Mixed Treatment Comparison ◽

Efficacy And Safety ◽

Treatment Comparison ◽

Disease Modifying Therapies ◽

Mixed Treatment ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Comparative Efficacy and Acceptability of Disease-Modifying Therapies in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Network Meta-Analysis

SSRN Electronic Journal ◽

10.2139/ssrn.3266988 ◽

2018 ◽

Author(s):

Jian Zhang ◽

Yueling Zhang ◽

Jian Tang ◽

Jinglian Luo ◽

Jiefeng Luo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Systematic Review ◽

Meta Analysis ◽

Comparative Efficacy ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

Current Medical Research and Opinion ◽

10.1185/03007995.2013.863755 ◽

2013 ◽

Vol 30 (4) ◽

pp. 613-627 ◽

Cited By ~ 45

Author(s):

Michael Hutchinson ◽

Robert J. Fox ◽

Eva Havrdova ◽

Nuwan C. Kurukulasuriya ◽

Sujata P. Sarda ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Mixed Treatment Comparison ◽

Efficacy And Safety ◽

Treatment Comparison ◽

Disease Modifying Therapies ◽

Mixed Treatment ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

Journal of Neurology ◽

10.1007/s00415-019-09395-w ◽

2019 ◽

Vol 267 (12) ◽

pp. 3489-3498 ◽

Cited By ~ 14

Author(s):

Huihui Li ◽

Fengli Hu ◽

Yanli Zhang ◽

Kai Li

Keyword(s):

Multiple Sclerosis ◽

Systematic Review ◽

Meta Analysis ◽

Comparative Efficacy ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Changing Disease Modifying Therapy Switching Dynamics for Relapsing-Remitting Multiple Sclerosis Patients

10.26226/morressier.59a3eda8d462b8028d895126 ◽

2017 ◽

Author(s):

Craig Wakeford

Keyword(s):

Multiple Sclerosis ◽

Disease Modifying Therapy ◽

Switching Dynamics ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Year one interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments

10.26226/morressier.5b7578605aff7400151f3263 ◽

2018 ◽

Cited By ~ 1

Author(s):

Thomas Leist

Keyword(s):

Multiple Sclerosis ◽

Interim Analysis ◽

Relapsing Remitting ◽

Phase Iiib ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Faculty Opinions recommendation of Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1145128.602265 ◽

2009 ◽

Author(s):

Dennis Bourdette ◽

Vijayshree Yadav

Keyword(s):

Multiple Sclerosis ◽

First Line ◽

Disease Modifying Therapy ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text